I am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter @theroberthart or email me at [email protected]
Preliminary results from late-stage clinical trials show that a booster shot of Pfizer and BioNTech’s Covid-19 vaccine is highly effective at preventing symptomatic disease, the companiesPfizer said it's Covid booster shot is over 95% effective at preventing symptomatic Covid-19.A booster shot was 95.6% effective at preventing symptomatic Covid-19 compared to those who did not receive an additional shot, the clinical trial of 10,000 people aged 16 and over showed.
The results showed the booster effectively restores the high levels of protection achieved after the second dose of the Pfizer-BioNTech shot. The trial was was conducted at a time when the delta variant of Covid-19 was prevalent, showed consistent efficacy regardless of age, sex, ethnicity and other factors, and raised no new safety concerns, with side effects consistent with other clinical studies. Pfizer chief executive Albert Bourla said the results show “further evidence of the benefits of boosters,” adding that the company plans to share the data with health officials around the world to help plan booster campaigns.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Pfizer, BioNTech report high efficacy of COVID-19 booster shot in studyPfizer Inc and German partner BioNTech SE on Thursday said data from a Phase III trial demonstrated high efficacy of a booster dose of their COVID-19 vaccine against the virus, including the Delta variant.
Les mer »
FDA authorizes booster doses of Moderna and Johnson & Johnson vaccines, says mix and match OKThe US Food and Drug Administration authorized booster doses of both Covid-19 vaccines made by Moderna and Johnson & Johnson Wednesday and also said any of the three authorized vaccines could be used as a booster in a 'mix and match' approach.
Les mer »
Booster shots could soon be recommended for people as young as 40, source saysBooster protection in the US could soon expand to a much broader population, as a source says the US government likely will soon recommend them to people as young as 40 who received either Moderna or Pfizer's Covid-19 vaccine.
Les mer »
Pfizer Vaccine 93% Effective At Preventing Hospitalization In Kids Ages 12-18More good news about the effectiveness of Pfizer’s COVID-19 vaccine in adolescents ages 12-18 — this time, about hospitalization rates The Centers for Disease Control and Prevention just rolled out new stats pointing to Pfizer’s COVID-19 vaccine being safe and effective at preventing hospitalization in kids ages 12-18. The CDC’s latest study shows that Pfizer’s […]
Les mer »
Pfizer vaccine is 93% effective in preventing Covid-19 hospitalization among adolescents, CDC study findsThe Pfizer/BioNTech vaccine is 93% effective in preventing hospitalization due to Covid-19 among children ages 12 to 18, according to a study by the US Centers for Disease Control and Prevention. Vaccine effectiveness differed only slightly within that age group, with 91% effectiveness for children age 12 to 15 and 94% effectiveness for those age 16 to 18.
Les mer »
Shaquille O'Neal says LeBron James on path to become greatest everShaquille O'Neal believes if LeBron James passes Kareem Abdul-Jabbar on NBA's all-time scoring list the Lakers star should be considered greatest ever.
Les mer »